39. Seysara


Active ingredient: sarecycline
Disease: Moderate to severe acne
Peak sales estimate: $150 million to $200 million
Approved: Oct. 1
Companies: Paratek Pharmaceuticals and Almirall 

The scoop: The FDA approved Seysara back-to-back with Paratek Pharmaceuticals' Nuzyra (omadacycline) antibiotic for community-acquired bacterial pneumonia and acute bacterial skin infections as the agency speeds up its new antibiotic approvals with concerns over growing antibiotic resistance. Seysara is an oral, once-daily, narrow-spectrum antibiotic derived from tetracycline for people over 9 years old with acne vulgaris. Paratek licensed Seysara’s U.S. commercialization rights to Allergan, which in turn passed them on to Barcelona-based Almirall through a $650 million selloff of its medical dermatology franchises this year. Paratek, which cashed in a $12 million milestone payment upon FDA approval, retains the rights to the drug for the rest of the world. Meanwhile, Almirall expects to launch Seysara after closing its deal with Allergan in January 2019. — Conor Hale 

39. Seysara

Suggested Articles

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.

The bispecific outperformed J&J’s blockbuster against an endpoint that tracked the proportion of patients achieving a 90% reduction in psoriasis,